CD274 and non-small cell lung carcinoma: In this study, as the pathological PD-L1 tests were performed a few months ago and most patients received antitumor therapies during this period, we divided the NSCLC patients into two groups based on whether the detection interval between the tissue-based PD-L1 test and the CTC-based PD-L1 analysis was less than 6 months (n=30) or greater than 6 months (n=32).